Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | |||||||||||||
PMID | (37832649) | ||||||||||||
Authors | Hoelzer D, Bassan R, Boissel N, Roddie C, Ribera JM, Jerkeman M, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org | ||||||||||||
Title | ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia. | ||||||||||||
|
|||||||||||||
URL | |||||||||||||
Abstract Text |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ABL1 fusion | acute lymphoblastic leukemia | sensitive | Dasatinib | Guideline | Actionable | Sprycel (dasatinib) is included in guidelines for patients with newly diagnosed Ph-like acute lymphoblastic leukemia harboring ABL1 fusion (PMID: 37832649; ESMO.org). | detail... 37832649 |